Ehlers-Danlos Syndrome (Classical Type)

Overview


Plain-Language Overview

Ehlers-Danlos Syndrome (Classical Type) is a genetic condition that affects the body's connective tissues, which provide strength and flexibility to the skin, joints, and blood vessels. People with this condition often have very stretchy skin that can be fragile and bruise easily. Their joints may be unusually flexible, leading to frequent dislocations or pain. The disorder primarily impacts the musculoskeletal system but can also affect the skin's appearance and healing. Because connective tissue is widespread, complications can involve multiple body systems. The condition is inherited and present from birth, affecting daily activities and sometimes causing chronic discomfort.

Clinical Definition

Ehlers-Danlos Syndrome (Classical Type) is a heritable connective tissue disorder characterized by defective collagen synthesis, primarily due to mutations in the COL5A1 or COL5A2 genes. This leads to abnormal type V collagen, resulting in skin hyperextensibility, joint hypermobility, and tissue fragility. The classical type is distinguished by its prominent cutaneous manifestations, including atrophic scarring and easy bruising, alongside musculoskeletal symptoms such as recurrent joint dislocations. The disorder follows an autosomal dominant inheritance pattern. Major clinical significance lies in the risk of chronic joint instability and skin complications, which can impair quality of life. Diagnosis is based on clinical features supported by molecular genetic testing.

Inciting Event

  • There is no specific external trigger; symptoms arise from inherited collagen defects present at birth.

  • Minor trauma or mechanical stress can precipitate joint dislocations or skin injury due to tissue fragility.

Latency Period

  • Symptoms such as skin hyperextensibility and joint hypermobility are often present from infancy or early childhood.

  • Diagnosis may be delayed despite early symptom onset due to variable expressivity and subtle initial signs.

Diagnostic Delay

  • Variable clinical presentation and overlap with other connective tissue disorders cause frequent misdiagnosis.

  • Lack of awareness and subtle early symptoms lead to delayed recognition of joint hypermobility syndrome.

  • Absence of a definitive laboratory test necessitates reliance on clinical criteria, which may be underutilized.

Clinical Presentation


Signs & Symptoms

  • Chronic joint pain and frequent joint dislocations or subluxations

  • Soft, velvety, and hyperextensible skin prone to bruising and poor healing

  • Atrophic, widened scars often described as 'cigarette paper' scars

  • Easy bruising and bleeding tendency without coagulation abnormalities

  • Muscle weakness and fatigue due to joint instability and connective tissue fragility

History of Present Illness

  • Patients report chronic joint pain and frequent joint dislocations or subluxations starting in childhood.

  • History of skin that stretches easily and wounds that heal with thin, atrophic scars is common.

  • Recurrent easy bruising and delayed wound healing are frequently described.

  • Some patients experience muscle weakness and fatigue related to joint instability.

Past Medical History

  • Previous episodes of joint dislocations or sprains without significant trauma are common.

  • History of poor wound healing or abnormal scarring after minor injuries or surgeries.

  • No specific medication or environmental exposures are typically associated with disease onset.

Family History

  • Autosomal dominant inheritance pattern with multiple affected family members across generations.

  • Relatives may have a history of joint hypermobility, skin hyperextensibility, or easy bruising.

  • Family history of spontaneous joint dislocations or poor wound healing supports diagnosis.

Physical Exam Findings

  • Skin hyperextensibility with smooth, velvety texture and abnormal wound healing

  • Joint hypermobility assessed by increased range of motion beyond normal limits

  • Atrophic scarring with thin, papyraceous scars often on the knees, elbows, and forehead

  • Molluscoid pseudotumors and subcutaneous spheroids over pressure points

  • Easy bruising with multiple ecchymoses in various stages of healing

Diagnostic Workup


Diagnostic Criteria

Diagnosis relies on the presence of major criteria including skin hyperextensibility and widened atrophic scars, combined with generalized joint hypermobility. Minor criteria include easy bruising, soft skin, and family history consistent with autosomal dominant inheritance. Confirmatory diagnosis is achieved through genetic testing identifying pathogenic variants in COL5A1 or COL5A2. Histopathology of skin biopsy showing abnormalities in collagen fibrils can support diagnosis but is less commonly used. Clinical evaluation using the Beighton score helps quantify joint hypermobility.

Pathophysiology


Key Mechanisms

  • Defective synthesis or processing of type V collagen due to mutations in the COL5A1 or COL5A2 genes leads to abnormal connective tissue structure.

  • Impaired collagen fibril formation results in weakened skin, joints, and blood vessel walls.

  • Increased tissue fragility causes skin hyperextensibility and joint hypermobility.

  • Abnormal collagen disrupts normal wound healing and increases risk of atrophic scarring.

  • Vascular fragility may contribute to easy bruising and bleeding complications.

InvolvementDetails
Organs

Skin shows hallmark features such as hyperextensibility, atrophic scarring, and easy bruising in classical Ehlers-Danlos syndrome.

Blood vessels may be fragile, increasing the risk of bruising and vascular complications, although less severe than in vascular EDS.

Tissues

Dermis is markedly affected, resulting in skin hyperextensibility and fragility due to defective collagen structure.

Joint capsule and ligaments exhibit laxity and weakness, leading to joint hypermobility and frequent dislocations.

Cells

Fibroblasts are responsible for producing defective type V collagen, leading to the characteristic connective tissue abnormalities in classical Ehlers-Danlos syndrome.

Chemical Mediators

Type V collagen is deficient or structurally abnormal due to mutations in COL5A1 or COL5A2, causing impaired collagen fibril formation and tissue fragility.

Treatments


Pharmacological Treatments

  • Analgesics

    • Mechanism:
      • Provide symptomatic relief of chronic musculoskeletal pain by modulating pain pathways.

    • Side effects:
      • Gastrointestinal upset

      • Renal impairment

      • Sedation

    • Clinical role:
      • Supportive

  • Vitamin C supplementation

    • Mechanism:
      • Enhances collagen synthesis by acting as a cofactor for prolyl and lysyl hydroxylase enzymes.

    • Side effects:
      • Gastrointestinal discomfort

      • Kidney stones in high doses

    • Clinical role:
      • Adjunctive

Non-pharmacological Treatments

  • Physical therapy focusing on joint stabilization and strengthening to reduce joint hypermobility and prevent dislocations.

  • Avoidance of high-impact activities and trauma to minimize risk of skin and joint injury.

  • Use of protective braces or splints to support hypermobile joints and prevent injury.

  • Regular cardiovascular monitoring to detect and manage potential vascular complications early.

Prevention


Pharmacological Prevention

  • Pain management with NSAIDs to reduce inflammation and discomfort

  • Use of vitamin C supplementation may support collagen synthesis though evidence is limited

  • Avoidance of corticosteroids which can worsen skin fragility

  • No specific pharmacologic agents prevent connective tissue defects in classical EDS

  • Prophylactic antibiotics are not routinely indicated unless wounds are infected

Non-pharmacological Prevention

  • Physical therapy focusing on joint stabilization and muscle strengthening

  • Avoidance of high-impact activities to reduce risk of joint injury

  • Protective padding and braces to prevent joint dislocations

  • Regular cardiovascular monitoring for early detection of valvular abnormalities

  • Patient education on skin care and injury prevention to minimize trauma

Outcome & Complications


Complications

  • Joint dislocations and subluxations leading to chronic instability

  • Severe skin lacerations with delayed healing and widened scars

  • Arterial rupture is rare but possible in classical type due to vessel fragility

  • Early-onset osteoarthritis from repetitive joint injury

  • Chronic pain syndrome impairing quality of life

Short-term Sequelae Long-term Sequelae
  • Acute joint dislocations causing pain and functional impairment

  • Skin tears and bruising after minor trauma

  • Wound dehiscence following injury or surgery

  • Localized swelling and inflammation after joint injury

  • Transient muscle spasms due to joint instability

  • Progressive joint degeneration and osteoarthritis

  • Permanent joint deformities from recurrent dislocations

  • Chronic pain and disability limiting daily activities

  • Extensive atrophic scarring with cosmetic and functional impact

  • Potential cardiovascular complications including valvular disease

Differential Diagnoses


Ehlers-Danlos Syndrome (Classical Type) versus Marfan Syndrome

Ehlers-Danlos Syndrome (Classical Type)

Marfan Syndrome

Autosomal dominant mutation in COL5A1 or COL5A2 genes

Autosomal dominant mutation in FBN1 gene

Skin hyperextensibility and widened atrophic scars

Aortic root dilation and ectopia lentis

Joint hypermobility with soft, velvety skin

Arachnodactyly, pectus excavatum, and tall stature

Ehlers-Danlos Syndrome (Classical Type) versus Loeys-Dietz Syndrome

Ehlers-Danlos Syndrome (Classical Type)

Loeys-Dietz Syndrome

Autosomal dominant mutation in COL5A1 or COL5A2 genes

Autosomal dominant mutation in TGFBR1 or TGFBR2 genes

No significant arterial tortuosity or hypertelorism

Arterial tortuosity and widely spaced eyes (hypertelorism)

Marked skin hyperextensibility with atrophic scars

Translucent skin with easy bruising but less skin hyperextensibility

Ehlers-Danlos Syndrome (Classical Type) versus Osteogenesis Imperfecta

Ehlers-Danlos Syndrome (Classical Type)

Osteogenesis Imperfecta

Autosomal dominant mutations in COL5A1 or COL5A2 genes

Mostly autosomal dominant mutations in COL1A1 or COL1A2 genes

Joint hypermobility and skin hyperextensibility without fractures

Multiple fractures with minimal trauma and blue sclerae

Normal bone density without fractures

Osteopenia and multiple healed fractures on X-ray

Ehlers-Danlos Syndrome (Classical Type) versus Cutis Laxa

Ehlers-Danlos Syndrome (Classical Type)

Cutis Laxa

Skin hyperextensibility with soft, velvety texture

Loose, sagging skin with decreased elasticity but not hyperextensible

Autosomal dominant mutations in COL5A1 or COL5A2 genes

Can be autosomal dominant, recessive, or acquired

Primarily skin and joint manifestations without emphysema

Pulmonary emphysema and hernias common

Ehlers-Danlos Syndrome (Classical Type) versus Benign Joint Hypermobility Syndrome

Ehlers-Danlos Syndrome (Classical Type)

Benign Joint Hypermobility Syndrome

Joint hypermobility with skin hyperextensibility and atrophic scars

Joint hypermobility without skin involvement or scarring

Autosomal dominant mutation in COL5A1 or COL5A2 genes

Often familial but no known specific gene mutation

Skin fragility and risk of vascular complications in some cases

Joint pain and dislocations without major vascular or skin complications

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.